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SUMMARY
The incidence rate of breast cancer (BC) continues to rise as the survival rate is still poor in economically
developing countries. Therapeutic approaches to improve cardiopulmonary functions and the survival rate of
BC survivors are pressing concerns. This study investigated the effects of progressive aerobic exercise on the
cardiopulmonary parameters of female BC survivors.
Fifty-eight BC survivors with stage I, II and III breast cancer, referred from the Radiotherapy and
Oncology Department of Lagos University Teaching Hospital, participated in the study and 48 of them
completed it. The participants were randomly assigned to groups A and B and each group was further
subdivided into subgroups 1 (premenopausal women) and 2 (postmenopausal women) based on their
menopausal status. Group A underwent aerobic exercise using the treadmill and also had educational and
counselling sessions while Group B had only educational and counselling sessions. Selected cardiopulmonary
parameters were measured at baseline, 3 ,6 , 9  and 12  weeks of intervention.   rd th th th
(1& 2)Significant improvements were observed in the cardiovascular variables of Groups A  (Resting systolic
1 2 1blood pressure (RSBP) (A :p = 0.00*; A : p = 0.01*), Resting diastolic blood pressure (RDBP) (A : p = 0.03*;
2 1 2 2A : p = 0.01*), Resting rate pressure product (RRPP) (A : p = 0.01*; A : p = 0.00*). With the exception of SaO
2 (1& 2) (p = 0.05*) of Group A , changes in the pulmonary variables of Groups A were not significant. No significant
(1& 2).differences were observed in the cardiovascular and pulmonary variables of Groups B
Aerobic exercise brought about significant therapeutic effects on selected cardiovascular parameters in
female BC survivors. 
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INTRODUCTION
Breast cancer (BC) is the commonest cancer affecting
women in Nigeria (Adebamowo and Ajayi, 2000).
According to global statistics on cancer, BC is the most
frequently diagnosed cancer among women worldwide and
the leading cause of cancer death among females,
accounting for 23% of total cancer cases and 14% of cancer
deaths (Jemal et al, 2011). It is a prevalent disease that
requires intense and prolonged treatment (Courneya et al,
2003). 
The survival rate of individuals with BC over the past
25 years has improved in the Western countries, resulting
in a substantial number of BC survivors (American Cancer
Society (ACS), 2012). In the United States of America, BC
survivors are estimated to exceed 12 million and 68% of
individuals diagnosed with cancer now live more than 5
years (ACS, 2012). This improvement in survival rate is
attributed to early detection of the disease and improvement
in cancer care (Jemal et al, 2011). In Nigeria, the survival
rate is still very low due to late detection of the disease and
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poor treatment compliance (Adesunkanmi et al, 2006).
Cardiopulmonary capacity may be compromised in BC
survivors because of the pathology of the disease,
therapeutic regimens, weight gain and inactivity secondary
to treatment (Brockstein et al, 2000; Gianni et al, 2001;
Courneya et al, 2003; Jones et al, 2010). Weight gain and
obesity are common occurrences in women diagnosed with
BC and these adversely increase the risk of cardiovascular
disease, hypertension, and diabetes (Calle et al, 1999;
Kopelman 2000; Demark-Wahnefried et al, 2001; McInnes
and Knobf, 2001). It was observed that cardiopulmonary
fitness was approximately 30% below that of age-matched
sedentary healthy women up to three years following the
completion of adjuvant therapy (Jones et al, 2007). The
precise causes of poor cardiopulmonary fitness are not
known but are probably a consequence of direct cytotoxic
therapy-associated injury to the cardiovascular system
together with lifestyle perturbations (e.g., deconditioning
and weight gain) (Jones et al, 2010). This reduction in
cardiopulmonary capacity may lead to reductions in QoL
and premature death (Courneya et al, 2003). Emerging
research evidence indicates that poor cardiopulmonary
fitness may be of central importance for certain adverse late
effects of the disease, including impaired left ventricular
ejection fraction, elevated cardiovascular disease (CVD)
risk profile, poor QoL, and fatigue following the
completion of adjuvant therapy for operable BC (Jones et
al, 2007; Herrero et al, 2006).
Therapeutic exercise has consistently been identified as
a central element of rehabilitation for many chronic diseases
and has been successful in improving QoL and reducing all-
cause mortality (McNeely et al, 2006). Observational
evidence suggests that moderate-intensity levels of aerobic
exercise may reduce the risk of death from BC and
therefore may prove to be a valuable intervention to
improve overall survival (Holmes et al, 2005). Some studies
from Western countries reported that moderate-intensity
aerobic training had significant improvement in the
cardiopulmonary parameters of BC survivors (Burnham and
Wilcox, 2002; Drouin, 2002; Courneya et al, 2003;
Crowley, 2003) while Segal et al (2001) reported that a
low-intensity aerobic exercise programme had no effect on
2aerobic fitness (VO peak) of BC patients receiving
chemotherapy. There is a dearth of knowledge on the
effects of therapeutic exercises on the cardiopulmonary
functions of BC survivors in Nigeria. Hence, this study was
designed to investigate the effects of progressive aerobic
exercise on the cardiovascular and pulmonary functions of
premenopausal and postmenopausal BC survivors.
METHODS
Research Design and Participants
This study was conducted in Lagos, Nigeria from 2012 to
2014. Fifty-eight (58) premenopausal and postmenopausal
BC survivors with stage I, II and III breast cancer were
recruited for the study through referrals by physicians from
the Radiotherapy and Oncology Department of Lagos
University Teaching Hospital (LUTH), Lagos, Nigeria.
They were screened for eligibility based on the inclusion
and exclusion criteria of the study. Breast cancer survivors
with severe orthopaedic and neurologic conditions, severe
cardiopulmonary pathologies, and contraindications to 
exercise as well as those that were involved in routine
exercises during the previous six months were excluded.
Four (4) were not eligible and therefore were excluded. The
remaining 54 eligible subjects were randomly assigned to
two groups (A and B). Each of the groups was further
subdivided into subgroup 1 and 2 based on the subjects’
menopausal status. The randomization was done using
computer-generated numbers. 
Forty-eight (48) subjects completed the study, while 6
subjects withdrew for reasons such as transportation
problems, inability to stay in the Lagos for the 12 weeks
duration of the study as well as exacerbation of side effects
of radiotherapy / chemotherapy (figure 1). Their ages
ranged from 30 to 74 years. Written informed consent was
obtained from all the subjects prior to participation. Ethical
approval was obtained prior to the study from the Health
Research and Ethics Committee of the Lagos University
Teaching Hospital, Idi-Araba, Lagos. 
Procedure
Group A underwent moderate-intensity aerobic exercise
using the treadmill while Group B (control group) had no
therapeutic exercise intervention but had group educational
and counselling sessions (for all subjects) for 30 minutes,
once every week. Baseline measurements of all the selected
cardiopulmonary outcome parameters for the subjects were
taken after a rest period of 15 minutes prior to the
intervention (Andersen et al, 2010). Resting systolic blood
pressure (RSBP) and resting diastolic blood pressure
(RDBP) were  measured with a  mercury
sphygmomanometer and a stethoscope in sitting position. 
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Resting heart rate (HR@rest) was measured with a
2stethoscope, SaO  with a pulse oximeter (unit) and FVC
with a hand-held micro spirometer. Resting rate pressure
product (RRPP) is the product of RSBP and HR@rest while
2VO max was calculated with the formula:
    (Uth et al, 2005)
Aerobic exercise at moderate intensity for subjects in group
A was the equivalent of their target heart rate (THR) and
was calculated using the Karvonen formula: 
THR = 0.6 (MHR ! HR@rest) + HR@rest (Tanaka
et al, 2001). 
On the appointment days, the vital signs of subjects in
group A were taken after a rest period of 15 minutes. This
was followed by a 5-minute warm-up exercise before
aerobic exercise on the treadmill and ended with a 5-minute
cool down exercise. Aerobic exercise on the treadmill was
for 15 minutes for the first 3 weeks and systematically
increased by 5 minutes every 3 weeks (Courneya et al,
2003). Exercise frequency was 3 days a week and
measurements of all the selected cardiopulmonary outcome
parameters were taken for all the subjects at the end of the
3 , 6 , 9  and 12  weeks. rd th th th
Data Analysis
Data was analysed using descriptive statistics of mean and
standard deviation. Results were illustrated in tables. The
Statistical Package for Social Sciences (SPSS) version 20.0
was used to analyse data. Repetitive analysis of variance
(ANOVA) was also used to determine the statistical
significance of the cardiovascular and pulmonary variables
across the baseline, end of 3 , 6 , 9  and 12  weeks forrd th th th
each group. The paired t test was used to compare the
baseline and end of 12  week mean values of cardiovascularth
and pulmonary variables within groups. The independent t
test was used to compare the changes in the selected
variables of premenopausal BC survivors with those of
postmenopausal BC survivors at the end of the 12 week.th 
Significant level was set at p #0.05.
Figure 1. Flow chart showing the recruitment and randomization of subjects into groups. 
R= Randomization. Group A= Aerobic exercise group, Group B= Control group, Subgroup 1=
Premenopausal BC survivors, Subgroup 2= Postmenopausal BC survivors, W=Withdrawal, TP=
Transport Problems, SET=Side Effects of Treatment exacerbated, LL=Left Lagos during the 12
weeks of study.
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RESULTS 
Following 12 weeks of study, repetitive ANOVA of data
taken at the end of 3 , 6 , 9  and 12  weeks showed thatrd th th th
there were statistically significant improvements in the
1cardiovascular variables of subjects in Group A  – RSBP (p
= 0.00*), RRPP (p = 0.05*) – while there were no
statistically significant improvements in the pulmonary
variables. Post-hoc analysis showed that significant changes
in RSBP occurred between the baseline and the 6  week,th
baseline and 9  week and baseline and 12  week.th th
Significant change in RRPP occurred between baseline and
12  week (table 1). There were also statistically significantth
improvements in the cardiovascular variables of subjects in
2Group A  – RSBP (p = 0.02*), RDBP (p = 0.00*), RRPP
(p = 0.04*) – while there were no statistically significant
improvements in the pulmonary variables. Post-hoc analysis
shows that the significant changes in RSBP and RRPP
occurred between baseline and the 12  week whileth
significant changes in RDBP occurred between the baseline
and the 9  week and between the baseline and the 12  weekth th
(table 1). No significant differences were observed in the
cardiovascular and pulmonary variables of subjects in
(1&2) Groups B (table 2). 
Paired t-test comparison of changes in cardiovascular
variables between pre-treatment (baseline) and post-
treatment (12  week) also showed that there wereth
statistically significant improvements in the cardiovascular
(1&2) 1variables of subjects in Groups A  – RSBP (A : p =
2 1 20.00*; A : p = 0.01*), RDBP (A : p = 0.03*; A : p =
1 20.01*), RRPP (A : p = 0.01*; A : p = 0.00*) while there
were no significant differences observed in the
(1&2) cardiovascular variables of subjects in Groups B (table
3). Although some changes were observed in some of the
(1&2), pulmonary variables of Groups A they did not attain
2statistically significant improvement levels except the SaO
2(p = 0.05*) of Group A . There were no significant
differences observed in the pulmonary variables of subjects
(1&2) in Groups B (table 4). 
With the exception of RDBP, improvements in the
cardiovascular variables of subjects in Group A were more
pronounced in the premenopausal BC survivors than in the
postmenopausal survivors. There was a significant
difference in the mean changes in RRPP (p=0.05*) of
premenopausal BC survivors compared to postmenopausal
BC survivors. The cumulative mean changes in all the
cardiovascular variables were more pronounced in Group
A compared with Group B (table 5). 
1 2Table 1. Changes in the cardiovascular and pulmonary variables of subjects in Group A and A
Variables Baseline
      (A)
3  Weekrd
      (B)
6  Weekth
      ( C)
9  Weekth
      (D)
12  Weekth






RSBP (mmHg) 123.00 ± 9.07 114.00±9.91 110.25 ± 8.51 106.75 ± 6.04 103.75±6.27 6.77 0.00* a&c, a&d
a&e
RDBP (mmHg) 79.50 ± 10.68 75.00±10.80 71.75 ± 9.04 70.50±5.93 67.75 ± 7.89 1.99 0.12
RRPP
(beats/min/mmHg)
9835.00 ± 1862.32 8911.00± 1579.69 8563.00 ± 1623.22 8091.00 ± 1614.36 7398.00± 1284.78 2.58 0.05* a&e
Pulmonary
2 SaO (%) 98.25 ± 0.71 98.13±0.83 98.00 ± 0.53 98.13 ± 1.13 98.50 ± 0.53 0.47 0.75
FVC (litres) 1.79 ± 0.50 1.95±0.55 2.04 ± 0.58 2.09 ± 0.63 2.25 ± 0.54 0.73 0.58
2VO max(kg/ml/min) 33.89 ± 4.34 34.93±4.53 35.34 ± 5.34 36.38 ± 6.09 38.42 ± 4.83 0.92 0.46
2GROUP A
CVS
RSBP (mmHg) 125.43±14.50 114.86±5.76 113.14±8.71 112.5 ±8.77 108.00±5.54 3.42 0.02* a&e
RDBP (mmHg) 84.57 ± 10.63 79.43±5.38 76.29 ± 4.23 72.29 ± 6.26 70.57 ± 3.78 5.19 0.00* a&d, a&e
RRPP
(beats/min/mmHg)
9192.00 ± 587.24 8761.14± 734.08 8381.71 ± 726.62 8408.00±1044.89 7834.29±787.97 2.83 0.04* a&e
Pulmonary
2 SaO (%) 97.43 ± 0.53 97.86±0.38 98.14 ± 0.69 98.00 ± 0.00 98.14 ± 0.69 2.22 0.09
FVC (litres) 1.70 ± 0.43 1.90±0.47 1.93 ± 0.47 2.01 ± 0.46 2.17 ± 0.49 0.93 0.46
2VO max(kg/ml/min 33.35 ± 2.67 32.21±3.66 32.76 ± 2.53 32.20 ± 1.97 33.35 ± 2.93 0.25 0.91
2=Key: RSBP=Resting Systolic Blood Pressure, RDBP= Resting Diastolic Blood Pressure, RRPP=Resting Rate Pressure Product, SaO Arterial
2Oxyhaemoglobin Saturation, FVC= Forced Vital Capacity, VO max=Maximal Oxygen Uptake, *= significant at p#0.05. 
4 AJPARS Vol. 8, Nos. 1 & 2, June 2016, pp.1 -9
Effect of Progressive Aerobic Exercise on Cardiopulmonary Functions of Breast Cancer Survivors







1GROUP A RSBP(mmHg) 123.00±9.07 103.75±6.27 4.94 0.00*
RDBP(mmHg) 79.50±10.68 67.75±7.89 2.50 0.03*
RRPP(beat/min/ mmHg) 9835.00±1862.32 7398.00±1284.78 3.05 0.01*
1GROUP B RSBP(mmHg) 117.00 ±14.70 117.00±16.73 0.00 1.00
RDBP(mmHg) 77.50 ± 17.08 75.50 ± 17.31 0.16 0.81
RRPP(beat/min/mmHg) 9848.00 ± 2862.41 10021.00 ± 2407.39 -0.09 0.93
Postmenopausal
2GROUP A RSBP(mmHg) 125.43±14.50 108.00±5.54 2.97 0.01*
RDBP(mmHg) 84.57±10.63 70.57±3.78 3.28 0.01*
RRPP(beat/min/mmHg) 9192.00±587.24 7834.29±787.97 3.66 0.00*











2=Key: RSBP=Resting Systolic Blood Pressure, RDBP= Resting Diastolic Blood Pressure, RRPP=Resting Rate Pressure Product, SaO Arterial
2Oxyhaemoglobin Saturation, FVC= Forced Vital Capacity, VO max=Maximal Oxygen Uptake. 
Table 3. Comparison of changes in cardiovascular variables between pre-treatment (baseline) and post-treatment (12  week) of theth
premenopausal and postmenopausal study groups
Variables Baseline
      (A)
3  Weekrd
      (B)
6  Weekth
      ( C)
9  Weekth
      (D)
12  Weekth




RSBP (mmHg) 117.00±15.87 117.00±22.24 115.50±17.23 112.50±16.36 117.00±18.07 0.05 1.00
RDBP (mmHg) 77.50 ± 17.08 76.50±16.52 76.00 ± 19.93 73.00 ± 16.37 75.50 ± 17.31 0.04 1.00
RRPP (beats/min/mmHg) 9848.00 ± 2862.41 10201.00 ± 2930.07 9448.00 ± 1180.59 10244.00 ± 1707.45 10021.00 ± 2407.39 0.08 0.99
Pulmonary
2 SaO (%) 98.75 ± 0.50 98.00 ± 0.00 98.00 ± 0.00 98.25 ± 0.50 98.00 ± 0.00 0.25 0.89
FVC (litres) 1.88 ± 0.49 1.98 ± 0.46 1.99 ± 0.54 2.05 ± 0.48 2.04 ± 0.45 0.08 0.99
2VO max(kg/ml/min) 33.09 ± 4.57 31.69 ± 4.21 30.73 ± 3.78 29.85 ± 2.51 32.25 ± 5.73 0.35 0.84
2GROUP B
CVS
RSBP (mmHg) 133.00±12.06 127.50±7.00 125.00±7.02 125.75±11.50 125.00±15.19 0.38 0.82
RDBP (mmHg) 89.00 ± 6.63 83.00±12.49 82.00 ± 5.42 83.00 ± 6.22 82.00 ± 2.83 0.63 0.65
RRPP (beats/min/mmHg) 11515.00 ± 1356.72 10696.00± 880.10 10724.00 ± 582.24 11029.00 ± 509.17 11058.00 ± 660.87 0.60 0.67
Pulmonary
2 SaO (%) 97.50 ± 1.73 97.75 ± 0.50 97.00 ± 0.82 97.75 ± 0.50 97.25 ± 0.96 0.42 0.79
FVC (litres) 1.62 ± 0.67 1.73 ± 0.49 1.75 ± 0.54 1.78 ± 0.49 1.77 ± 0.53 0.06 0.99
2VO max(kg/ml/min 29.37 ± 1.60 30.37 ± 2.91 29.63 ± 2.44 28.87 ± 1.54 28.24 ± 1.57 0.59 0.68
Key: RSBP=Resting Systolic Blood Pressure, RDBP=Resting Diastolic Blood Pressure, RRPP=Resting Rate Pressure Product, *= significant at p<0.05
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Table 4. Comparison of changes in pulmonary variables between pre-treatment (baseline) and post-treatment (12  week) of theth







1 2GROUP A SaO (%) 98.25±0.71 98.50±0.54 -0.80 0.44
FVC(litre) 1.79± 0.50 2.25±0.54 -1.78 0.1
2VO max(kg/ml/min) 33.89±4.34 38.42±4.83 -1.98 0.07
1 2GROUP B SaO (%) 98.75±0.50 98.00±0.00 1.87 0.09
FVC(litre) 1.88±0.49 2.04±0.45 0.48 0.65
2VO max(kg/ml/min) 33.09±4.57 32.25±5.73 0.23 0.83
Postmenopausal
2 2GROUP A SaO (%) 97.43±0.54 98.14±0.69 -2.17 0.05*
FVC(litre) 1.70±0.43 2.17±0.49 -1.90 0.08
2VO max(kg/ml/min) 33.35±2.67 33.35±2.93 -0.00 1
2 2GROUP B SaO (%) 97.50±1.73 97.25±0.96 0.25 0.81
FVC(litre) 1.62±0.67 1.77±0.53 -0.35 0.74
2VO max(kg/ml/min) 29.37±1.60 28.24±1.57 1.01 0.35
2= 2Key: SaO Arterial Oxyhaemoglobin Saturation, FVC= Forced Vital Capacity, VO max=Maximal Oxygen Uptake, *= significant at p<0.05
Table 5. Comparison of changes in cardiovascular / pulmonary variables of premenopausal BCS with that of postmenopausal BCS and the
cumulative mean changes in the variables of different groups at the 12  week th




t-value p-value Cumulative Mean
Change
A RSBP(mmHg) 19.25 17.43 0.39 0.71 36.68
RDBP(mmHg) 11.75 14.00 -0.61 0.55 25.75
RRPP(beat/min/mmHg) 2437.00 1357.71 2.19 0.05* 3794.71
B RSBP(mmHg) 0.00 8.00 -0.26 0.81 8
RDBP(mmHg) 2.00 7.00 -1.73 0.13 9
RRPP(beat/min/mmHg) -173.00 457.00 0.22 0.84 284
2A SaO (%) -0.25 -0.71 -1.89 0.08 -0.96
FVC(litre) -0.46 -0.46 -0.04 0.97 -0.92
2VO max(kg/ml/min) -4.54 -0.01 2.52 0.03* -4.55
2B SaO (%) 0.75 0.25 -1.85 0.11 1
FVC(litre) -0.16 -0.15 0.15 0.88 -0.31
2VO max(kg/ml/min) 0.84 1.14 0.77 0.47 1.98
2=Key: RSBP=Resting Systolic Blood Pressure, RDBP= Resting Diastolic Blood Pressure, RRPP=Resting Rate Pressure Product, SaO Arterial
2Oxyhaemoglobin Saturation, FVC = Forced Vital Capacity, VO max=Maximal Oxygen Uptake, BCS=Breast cancer survivors
2Improvements in the VO max (a pulmonary variable) of
Group A were more pronounced in the premenopausal BC
survivors than in postmenopausal BC survivors. There was
2a significant difference in the mean changes in VO max
(p=0.03*) between premenopausal and postmenopausal BC
survivors. The cumulative mean changes in all the
pulmonary variables were more pronounced in Group A
than in Group B (table 5).
DISCUSSION
The significant differences observed in two of the
1cardiovascular parameters (RSBP and RRPP) of Group A
and in all the three cardiovascular parameters (RSBP,
2 RDBP and RRPP) of Group A imply that aerobic exercise
using the treadmill had significant therapeutic effects on the
cardiovascular parameters of the premenopausal and
postmenopausal BC survivors. These significant therapeutic
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effects in RSBP occurred earlier in premenopausal BC
survivors (end of 6  week) than in postmenopausal BCth
survivors (end of 12  week) while that of RRPP occurredth
at the same time (end of 12  week) in the 2 groups.th
Significant therapeutic effect in RDBP occurred only in the
postmenopausal BC survivors at the end of the 9  week andth
continued to the end of the 12  week. These significantth
therapeutic effects of aerobic exercise on the cardiovascular
parameters of premenopausal and postmenopausal BC
survivors were further buttressed by the changes in
cardiovascular variables between pre-treatment and post-
treatment, where all the cardiovascular parameters (RSBP,
RDBP and RRPP) showed significant improvements in the
2 groups of BC survivors. These findings may be due to the
fact that aerobic exercise improves myocardial circulation
and metabolism which in turn protects the heart from
hypoxic stress, and also enhances glycolytic capacity as
reported by Pollock et al (2000). This improvement of
myocardial circulation and metabolism improves the heart’s
oxygen supply and its contractility during a specific
challenge, thus the heart rate and blood pressure are
favourably lowered, so that the work of the myocardium is
significantly reduced at rest and during exercise. Aerobic
exercise using the treadmill brought about more significant
therapeutic improvements in the RSBP and RRPP of the
premenopausal BC survivors than the postmenopausal BC
survivors but in RDBP, the reverse was the case.     
Although there were changes in the 3 pulmonary
2, 2 1 2parameters (SaO  FVC and VO max) of Groups A and A ,
they were not statistically significant except in the
2 2comparison of SaO  in Group A  between pre-treatment and
post-treatment. This implies that aerobic exercise using the
treadmill showed signs of effecting therapeutic
improvements in the pulmonary parameters of both
premenopausal and postmenopausal BC survivors. The
reason for this may be that the long-term effect of exercise
leads to expansion of the oxygen transport system, which is
reflected by the augmented capacity for maximal work
(Wilmore and Costill, 2005). It results in larger lung size
and vital capacity, higher blood volume and total
haemoglobin, larger stroke volume, maximal oxygen uptake
and arterio-venous oxygen difference. Aerobic exercise
using the treadmill brought about more beneficial effect on
2the VO max of the premenopausal BC survivors than that
of the postmenopausal BC survivors. The reverse was the
2 case for SaO while it had equal effects on the FVC of the
2 groups of BC survivors. 
These findings are partly consistent with the results of
previous studies that reported that moderate intensity
aerobic training brought about significant improvements in
the cardiopulmonary parameters of study participants
(Burnham and Wilcox, 2002; Drouin, 2002; Courneya et
al, 2003; Crowley, 2003). However, the findings of these
studies on significant improvement in the pulmonary
functions of the subjects differ slightly with that of the
present study and this may be due to differences in the
duration of exercise intervention. The duration of exercise
intervention by Courneya et al (2003) was 15 weeks while
this study was 12 weeks. Some studies combined aerobic,
resistance and stretching exercises for each participant to
achieve an individualized, prescriptive exercise which was
carried out for 6 months (Schneider et al, 2003; Schneider
et al, 2007; Hsieh et al, 2008). Schneider et al (2007)
reported that moderate intensity, individualized,
prescriptive exercise maintains or improves cardiovascular
and pulmonary function during and after cancer treatment.
Segal et al (2001) reported that low intensity aerobic
exercise programme had no effects on the aerobic fitness
2(VO peak) of BC patients receiving chemotherapy. 
The limitation of this study was the relative small
sample size due to the fact that many BC survivors were
unwilling to participate in the study because of the side
effects of chemotherapy and/or radiotherapy, in particular
the cancer-related fatigue (CRF) that they were
experiencing at the time of the study. Some of those who
were willing to participate in the study were referred to the
hospital for treatment from hospitals in other states of the
country; therefore, they were unable to stay for the total
duration of the study. These factors also accounted for the
delay in completion of the study. 
Based on the findings of this study, it is therefore
recommended that progressive aerobic exercise training,
prescribed and supervised by physiotherapists, should be
included in the management of BC survivors in order to
improve their cardiovascular fitness.
Conclusion 
Aerobic exercise brought about significant therapeutic
effects on selected cardiovascular parameters in female BC
survivors. Improvements in the cardiovascular variables of
subjects that performed progressive aerobic exercise using
the treadmill were more pronounced in premenopausal BC
survivors than in postmenopausal BC survivors.
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